Switch theme
Sign up to access all valuation multiples
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.
2007
287
LTM Revenue $48.3M
LTM EBITDA $2.6M
$104M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aroa Biosurgery has a last 12-month revenue (LTM) of $48.3M and a last 12-month EBITDA of $2.6M.
In the most recent fiscal year, Aroa Biosurgery achieved revenue of $40.7M and an EBITDA of -$2.8M.
Aroa Biosurgery expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aroa Biosurgery valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $48.3M | XXX | $40.7M | XXX | XXX | XXX |
| Gross Profit | $41.4M | XXX | $34.8M | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 85% | XXX | XXX | XXX |
| EBITDA | $2.6M | XXX | -$2.8M | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | -7% | XXX | XXX | XXX |
| EBIT | -$0.4M | XXX | -$9.9M | XXX | XXX | XXX |
| EBIT Margin | -1% | XXX | -24% | XXX | XXX | XXX |
| Net Profit | -$1.6M | XXX | -$6.3M | XXX | XXX | XXX |
| Net Margin | -3% | XXX | -15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Aroa Biosurgery's stock price is AUD 1 (or $0).
Aroa Biosurgery has current market cap of AUD 176M (or $113M), and EV of AUD 162M (or $104M).
See Aroa Biosurgery trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $104M | $113M | XXX | XXX | XXX | XXX | $-0.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Aroa Biosurgery has market cap of $113M and EV of $104M.
Aroa Biosurgery's trades at 2.6x EV/Revenue multiple, and -65.7x EV/EBITDA.
Equity research analysts estimate Aroa Biosurgery's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aroa Biosurgery has a P/E ratio of -65.5x.
See valuation multiples for Aroa Biosurgery and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $113M | XXX | $113M | XXX | XXX | XXX |
| EV (current) | $104M | XXX | $104M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 36.8x | XXX | -65.7x | XXX | XXX | XXX |
| EV/EBIT | -265.7x | XXX | -12.0x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -65.5x | XXX | -23.8x | XXX | XXX | XXX |
| EV/FCF | -46.6x | XXX | -12.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAroa Biosurgery's last 12 month revenue growth is 19%
Aroa Biosurgery's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Aroa Biosurgery's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aroa Biosurgery's rule of X is 52% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Aroa Biosurgery and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | -4% | XXX | XXX | XXX |
| EBITDA Growth | 84% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 15% | XXX | 15% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 52% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 90% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 110% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aroa Biosurgery acquired XXX companies to date.
Last acquisition by Aroa Biosurgery was XXXXXXXX, XXXXX XXXXX XXXXXX . Aroa Biosurgery acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Aroa Biosurgery founded? | Aroa Biosurgery was founded in 2007. |
| Where is Aroa Biosurgery headquartered? | Aroa Biosurgery is headquartered in Australia. |
| How many employees does Aroa Biosurgery have? | As of today, Aroa Biosurgery has 287 employees. |
| Is Aroa Biosurgery publicy listed? | Yes, Aroa Biosurgery is a public company listed on ASX. |
| What is the stock symbol of Aroa Biosurgery? | Aroa Biosurgery trades under ARX ticker. |
| When did Aroa Biosurgery go public? | Aroa Biosurgery went public in 2020. |
| Who are competitors of Aroa Biosurgery? | Similar companies to Aroa Biosurgery include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Aroa Biosurgery? | Aroa Biosurgery's current market cap is $113M |
| What is the current revenue of Aroa Biosurgery? | Aroa Biosurgery's last 12 months revenue is $48.3M. |
| What is the current revenue growth of Aroa Biosurgery? | Aroa Biosurgery revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of Aroa Biosurgery? | Current revenue multiple of Aroa Biosurgery is 2.0x. |
| Is Aroa Biosurgery profitable? | Yes, Aroa Biosurgery is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Aroa Biosurgery? | Aroa Biosurgery's last 12 months EBITDA is $2.6M. |
| What is Aroa Biosurgery's EBITDA margin? | Aroa Biosurgery's last 12 months EBITDA margin is 5%. |
| What is the current EV/EBITDA multiple of Aroa Biosurgery? | Current EBITDA multiple of Aroa Biosurgery is 36.8x. |
| What is the current FCF of Aroa Biosurgery? | Aroa Biosurgery's last 12 months FCF is -$2.1M. |
| What is Aroa Biosurgery's FCF margin? | Aroa Biosurgery's last 12 months FCF margin is -4%. |
| What is the current EV/FCF multiple of Aroa Biosurgery? | Current FCF multiple of Aroa Biosurgery is -46.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
